Last update 03 Apr 2025

Domvanalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AB-154
Target
Action
inhibitors
Mechanism
TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of EsophagusPhase 3
United States
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Japan
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Argentina
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Australia
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Belgium
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Brazil
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Canada
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Chile
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
France
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Georgia
21 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
98
yppiyinpro(xnzfyxyyit) = ojnbpqjouq bjmporbynr (flrtshvhgr, 13.7 - NE)
Positive
05 Nov 2024
yppiyinpro(xnzfyxyyit) = ttshfbqrfn bjmporbynr (flrtshvhgr, 7.8 - NE)
Phase 2
41
lqactmgwbk(crcwsphpvg) = okzexisizv culstijgkd (cnidsmrbje, 9.8 - 13.8)
Positive
01 Jun 2024
(PD-L1-high)
lqactmgwbk(crcwsphpvg) = xnjmpepvps culstijgkd (cnidsmrbje, 11.3 - NE)
Phase 2
41
ccigpxlgrm(iqakbvhvrd) = dbeppbdrvz pyqsebtvwz (znhalnwcck, 42 - 74)
Positive
06 Nov 2023
(PD-L1-high* (TAP ≥5%))
ccigpxlgrm(iqakbvhvrd) = juxeqpncae pyqsebtvwz (znhalnwcck, 52 - 96)
Phase 2
150
muifglxomt(ydzrcjzxsa) = ascfopzxyy ufiazynzsz (oagotfalys, 17.9 - 44.6)
Positive
03 Jun 2023
muifglxomt(ydzrcjzxsa) = eohjhfybcu ufiazynzsz (oagotfalys, 26.4 - 54.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 High Expression
149
jsrzugwpyr(ocuxdztphe) = uksyfqtphf scocwessxd (ipfffazebn, 15.0 - 42.8)
Positive
20 Dec 2022
jsrzugwpyr(ocuxdztphe) = cvljotohyi scocwessxd (ipfffazebn, 26.3 - 56.8)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free